Capricor Therapeutics (CAPR) Competitors

$28.01 -0.78 (-2.71%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$28.32 +0.31 (+1.11%)

As of 05/18/2026 07:38 PM Eastern

CAPR vs. KYMR, QGEN, PTGX, SYRE, and TGTX

Should you buy Capricor Therapeutics stock or one of its competitors? MarketBeat compares Capricor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capricor Therapeutics include Kymera Therapeutics (KYMR), Qiagen (QGEN), Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Capricor Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Capricor Therapeutics had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 16 mentions for Capricor Therapeutics and 9 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.30 beat Capricor Therapeutics' score of -0.07 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

21.7% of Capricor Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Capricor Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	167.14	-$311.35M	-$3.57	N/A
Capricor Therapeutics	$22.27M	72.84	-$105.04M	-$2.32	N/A

Kymera Therapeutics has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

Kymera Therapeutics presently has a consensus target price of $118.10, suggesting a potential upside of 48.23%. Capricor Therapeutics has a consensus target price of $48.36, suggesting a potential upside of 72.67%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Capricor Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Kymera Therapeutics beats Capricor Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Capricor Therapeutics compare to Qiagen?

Capricor Therapeutics (NASDAQ:CAPR) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Capricor Therapeutics currently has a consensus target price of $48.36, indicating a potential upside of 72.67%. Qiagen has a consensus target price of $44.98, indicating a potential upside of 33.17%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Capricor Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Qiagen has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	72.84	-$105.04M	-$2.32	N/A
Qiagen	$2.09B	3.33	$424.88M	$1.91	17.68

Qiagen has a net margin of 19.16% compared to Capricor Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Qiagen	19.16%	14.40%	8.40%

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Capricor Therapeutics had 6 more articles in the media than Qiagen. MarketBeat recorded 16 mentions for Capricor Therapeutics and 10 mentions for Qiagen. Qiagen's average media sentiment score of 0.36 beat Capricor Therapeutics' score of -0.07 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Qiagen beats Capricor Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Capricor Therapeutics currently has a consensus target price of $48.36, indicating a potential upside of 72.67%. Protagonist Therapeutics has a consensus target price of $113.69, indicating a potential upside of 12.86%. Given Capricor Therapeutics' higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Capricor Therapeutics has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	72.84	-$105.04M	-$2.32	N/A
Protagonist Therapeutics	$46.02M	140.78	-$130.15M	-$1.81	N/A

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Capricor Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Capricor Therapeutics has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

In the previous week, Capricor Therapeutics had 10 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 16 mentions for Capricor Therapeutics and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.12 beat Capricor Therapeutics' score of -0.07 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Protagonist Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics presently has a consensus target price of $90.25, suggesting a potential upside of 28.78%. Capricor Therapeutics has a consensus target price of $48.36, suggesting a potential upside of 72.67%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Spyre Therapeutics' return on equity of -42.88% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Capricor Therapeutics	N/A	-59.27%	-48.65%

In the previous week, Capricor Therapeutics had 11 more articles in the media than Spyre Therapeutics. MarketBeat recorded 16 mentions for Capricor Therapeutics and 5 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.16 beat Capricor Therapeutics' score of -0.07 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Spyre Therapeutics has a beta of 3.12, meaning that its share price is 212% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Capricor Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	6,837.92	-$155.20M	-$2.08	N/A
Capricor Therapeutics	$22.27M	72.84	-$105.04M	-$2.32	N/A

Summary

Spyre Therapeutics beats Capricor Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

TG Therapeutics has a net margin of 65.95% compared to Capricor Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Capricor Therapeutics	N/A	-59.27%	-48.65%

In the previous week, Capricor Therapeutics had 15 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Capricor Therapeutics and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.30 beat Capricor Therapeutics' score of -0.07 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.81	$447.18M	$2.86	13.80
Capricor Therapeutics	$22.27M	72.84	-$105.04M	-$2.32	N/A

TG Therapeutics currently has a consensus price target of $52.50, indicating a potential upside of 32.98%. Capricor Therapeutics has a consensus price target of $48.36, indicating a potential upside of 72.67%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

TG Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Capricor Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67B	$8.09B	$6.25B	$12.29B
Dividend Yield	N/A	2.54%	2.80%	5.30%
P/E Ratio	-12.07	16.00	20.86	25.23
Price / Sales	72.84	8.14	549.88	74.61
Price / Cash	N/A	16.74	27.48	37.30
Price / Book	5.07	3.58	9.67	6.63
Net Income	-$105.04M	$224.05M	$3.56B	$335.59M
7 Day Performance	-11.14%	-2.35%	-1.71%	-1.20%
1 Month Performance	-19.28%	-3.00%	-2.67%	-1.16%
1 Year Performance	170.11%	0.66%	30.01%	28.10%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.2577 of 5 stars	$28.01 -2.7%	$48.36 +72.7%	+196.7%	$1.67B	$22.27M	N/A	101	Earnings Report
KYMR Kymera Therapeutics	2.3667 of 5 stars	$83.55 -0.7%	$118.10 +41.3%	+163.4%	$6.92B	$39.21M	N/A	170
QGEN Qiagen	4.5802 of 5 stars	$33.67 +3.2%	$46.38 +37.8%	-24.8%	$6.72B	$2.09B	17.58	5,654	Dividend Increase Analyst Forecast
PTGX Protagonist Therapeutics	1.9818 of 5 stars	$99.95 -3.4%	$113.69 +13.7%	+126.4%	$6.66B	$46.02M	N/A	120
SYRE Spyre Therapeutics	2.7486 of 5 stars	$75.04 -1.8%	$90.25 +20.3%	+361.7%	$6.64B	$890K	N/A	73	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. KYMR, QGEN, PTGX, SYRE, and TGTX

How does Capricor Therapeutics compare to Kymera Therapeutics?

Summary

How does Capricor Therapeutics compare to Qiagen?

Summary

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Summary

How does Capricor Therapeutics compare to Spyre Therapeutics?

Summary

How does Capricor Therapeutics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. KYMR, QGEN, PTGX, SYRE, and TGTX

How does Capricor Therapeutics compare to Kymera Therapeutics?

Does the media favor KYMR or CAPR?

Do institutionals & insiders have more ownership in KYMR or CAPR?

Which has stronger valuation and earnings, KYMR or CAPR?

Which has more risk and volatility, KYMR or CAPR?

Do analysts recommend KYMR or CAPR?

Is KYMR or CAPR more profitable?

Summary

How does Capricor Therapeutics compare to Qiagen?

Do analysts prefer CAPR or QGEN?

Which has more risk & volatility, CAPR or QGEN?

Which has higher valuation and earnings, CAPR or QGEN?

Is CAPR or QGEN more profitable?

Do institutionals and insiders believe in CAPR or QGEN?

Does the media favor CAPR or QGEN?

Summary

How does Capricor Therapeutics compare to Protagonist Therapeutics?

Do analysts prefer CAPR or PTGX?

Which has higher valuation and earnings, CAPR or PTGX?

Do institutionals and insiders believe in CAPR or PTGX?

Which has more risk & volatility, CAPR or PTGX?

Is CAPR or PTGX more profitable?

Does the media favor CAPR or PTGX?

Summary

How does Capricor Therapeutics compare to Spyre Therapeutics?

Do institutionals and insiders hold more shares of SYRE or CAPR?

Do analysts prefer SYRE or CAPR?

Is SYRE or CAPR more profitable?

Does the media prefer SYRE or CAPR?

Which has more volatility and risk, SYRE or CAPR?

Which has higher earnings & valuation, SYRE or CAPR?

Summary

How does Capricor Therapeutics compare to TG Therapeutics?

Is TGTX or CAPR more profitable?

Does the media favor TGTX or CAPR?

Which has preferable valuation & earnings, TGTX or CAPR?

Do analysts prefer TGTX or CAPR?

Which has more volatility & risk, TGTX or CAPR?

Do insiders and institutionals hold more shares of TGTX or CAPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools